Logo image of BTAI

BIOXCEL THERAPEUTICS INC (BTAI) Stock Fundamental Analysis

USA - NASDAQ:BTAI - US09075P2048 - Common Stock

1.855 USD
+0.12 (+6.61%)
Last: 11/20/2025, 1:07:02 PM
Fundamental Rating

1

Taking everything into account, BTAI scores 1 out of 10 in our fundamental rating. BTAI was compared to 533 industry peers in the Biotechnology industry. Both the profitability and financial health of BTAI have multiple concerns. BTAI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTAI has reported negative net income.
In the past year BTAI has reported a negative cash flow from operations.
In the past 5 years BTAI always reported negative net income.
BTAI had a negative operating cash flow in each of the past 5 years.
BTAI Yearly Net Income VS EBIT VS OCF VS FCFBTAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

BTAI has a worse Return On Assets (-152.28%) than 85.37% of its industry peers.
Industry RankSector Rank
ROA -152.28%
ROE N/A
ROIC N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTAI Yearly ROA, ROE, ROICBTAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BTAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTAI Yearly Profit, Operating, Gross MarginsBTAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

BTAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BTAI has more shares outstanding
Compared to 5 years ago, BTAI has more shares outstanding
Compared to 1 year ago, BTAI has a worse debt to assets ratio.
BTAI Yearly Shares OutstandingBTAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
BTAI Yearly Total Debt VS Total AssetsBTAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -25.48, we must say that BTAI is in the distress zone and has some risk of bankruptcy.
BTAI has a Altman-Z score of -25.48. This is amonst the worse of the industry: BTAI underperforms 86.87% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.48
ROIC/WACCN/A
WACC8.63%
BTAI Yearly LT Debt VS Equity VS FCFBTAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

BTAI has a Current Ratio of 1.17. This is a normal value and indicates that BTAI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BTAI (1.17) is worse than 86.30% of its industry peers.
A Quick Ratio of 1.16 indicates that BTAI should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.16, BTAI is doing worse than 86.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 1.16
BTAI Yearly Current Assets VS Current LiabilitesBTAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.93% over the past year.
Looking at the last year, BTAI shows a very negative growth in Revenue. The Revenue has decreased by -66.96% in the last year.
EPS 1Y (TTM)71.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.42%
Revenue 1Y (TTM)-66.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.21%

3.2 Future

BTAI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.23% yearly.
Based on estimates for the next years, BTAI will show a very strong growth in Revenue. The Revenue will grow by 126.84% on average per year.
EPS Next Y78.42%
EPS Next 2Y35.85%
EPS Next 3Y25.23%
EPS Next 5Y15.23%
Revenue Next Year-74.15%
Revenue Next 2Y29.14%
Revenue Next 3Y200.07%
Revenue Next 5Y126.84%

3.3 Evolution

BTAI Yearly Revenue VS EstimatesBTAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
BTAI Yearly EPS VS EstimatesBTAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BTAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BTAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTAI Price Earnings VS Forward Price EarningsBTAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTAI Per share dataBTAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as BTAI's earnings are expected to grow with 25.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.85%
EPS Next 3Y25.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTAI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOXCEL THERAPEUTICS INC

NASDAQ:BTAI (11/20/2025, 1:07:02 PM)

1.855

+0.12 (+6.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners4.61%
Inst Owner Change268.07%
Ins Owners0.41%
Ins Owner Change25.19%
Market Cap36.45M
Revenue(TTM)752.00K
Net Income(TTM)-68.21M
Analysts78.18
Price Target21.83 (1076.82%)
Short Float %7.35%
Short Ratio1.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.46%
Min EPS beat(2)-81.51%
Max EPS beat(2)-29.42%
EPS beat(4)2
Avg EPS beat(4)3.13%
Min EPS beat(4)-81.51%
Max EPS beat(4)77.91%
EPS beat(8)5
Avg EPS beat(8)15.2%
EPS beat(12)5
Avg EPS beat(12)3.84%
EPS beat(16)7
Avg EPS beat(16)3.18%
Revenue beat(2)0
Avg Revenue beat(2)-53.86%
Min Revenue beat(2)-54.79%
Max Revenue beat(2)-52.94%
Revenue beat(4)0
Avg Revenue beat(4)-54.59%
Min Revenue beat(4)-61.4%
Max Revenue beat(4)-49.22%
Revenue beat(8)2
Avg Revenue beat(8)-35.61%
Revenue beat(12)2
Avg Revenue beat(12)-39.69%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.12%
EPS NQ rev (1m)4.73%
EPS NQ rev (3m)23.84%
EPS NY rev (1m)-3.53%
EPS NY rev (3m)20.09%
Revenue NQ rev (1m)-1.62%
Revenue NQ rev (3m)-34.82%
Revenue NY rev (1m)-7.57%
Revenue NY rev (3m)-49.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 48.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.7
EYN/A
EPS(NY)-4.01
Fwd EYN/A
FCF(TTM)-2.96
FCFYN/A
OCF(TTM)-2.96
OCFYN/A
SpS0.04
BVpS-4.53
TBVpS-4.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -152.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 1.16
Altman-Z -25.48
F-Score2
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.42%
EPS Next Y78.42%
EPS Next 2Y35.85%
EPS Next 3Y25.23%
EPS Next 5Y15.23%
Revenue 1Y (TTM)-66.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.21%
Revenue Next Year-74.15%
Revenue Next 2Y29.14%
Revenue Next 3Y200.07%
Revenue Next 5Y126.84%
EBIT growth 1Y32.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.79%
EBIT Next 3Y13.12%
EBIT Next 5Y13.6%
FCF growth 1Y65.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.1%
OCF growth 3YN/A
OCF growth 5YN/A

BIOXCEL THERAPEUTICS INC / BTAI FAQ

Can you provide the ChartMill fundamental rating for BIOXCEL THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to BTAI.


What is the valuation status of BIOXCEL THERAPEUTICS INC (BTAI) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOXCEL THERAPEUTICS INC (BTAI). This can be considered as Overvalued.


What is the profitability of BTAI stock?

BIOXCEL THERAPEUTICS INC (BTAI) has a profitability rating of 0 / 10.


How financially healthy is BIOXCEL THERAPEUTICS INC?

The financial health rating of BIOXCEL THERAPEUTICS INC (BTAI) is 1 / 10.